MDT

98.76

+2.13%↑

145.85

-1.34%↓

VEEV

219.49

-1.71%↓

HQY

87.3

+1.61%↑

NEOG

9.53

+3.36%↑

MDT

98.76

+2.13%↑

145.85

-1.34%↓

VEEV

219.49

-1.71%↓

HQY

87.3

+1.61%↑

NEOG

9.53

+3.36%↑

MDT

98.76

+2.13%↑

145.85

-1.34%↓

VEEV

219.49

-1.71%↓

HQY

87.3

+1.61%↑

NEOG

9.53

+3.36%↑

MDT

98.76

+2.13%↑

145.85

-1.34%↓

VEEV

219.49

-1.71%↓

HQY

87.3

+1.61%↑

NEOG

9.53

+3.36%↑

MDT

98.76

+2.13%↑

145.85

-1.34%↓

VEEV

219.49

-1.71%↓

HQY

87.3

+1.61%↑

NEOG

9.53

+3.36%↑

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Open

SectorHealthcare

503.24 3.03

Buy Sell

Overview

Share price change

24h

Current

Min

487.17

Max

508.12

Key metrics
By Trading Economics
Income	-72M -114M
Sales	74M 287M
Profit margin	-39.75
Employees	528
EBITDA	-68M -106M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+28.82% upside

Dividends
By Dow Jones
Next Earnings	25 lut 2026

Market Stats
By TradingEconomics
Market Cap	2.4B 12B
Previous open	500.21
Previous close	503.24

News Sentiment

By Acuity

30%

70%

56 / 361 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 sty 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15 sty 2026, 00:00 UTC

Earnings

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14 sty 2026, 23:47 UTC

Market Talk

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14 sty 2026, 23:44 UTC

Market Talk

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14 sty 2026, 23:39 UTC

Market Talk

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14 sty 2026, 23:32 UTC

Market Talk

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14 sty 2026, 22:56 UTC

Acquisitions, Mergers, Takeovers

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14 sty 2026, 22:53 UTC

Acquisitions, Mergers, Takeovers

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14 sty 2026, 22:17 UTC

Market Talk

Global Equities Roundup: Market Talk

14 sty 2026, 22:17 UTC

Market Talk

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14 sty 2026, 22:09 UTC

Earnings

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14 sty 2026, 22:08 UTC

Earnings

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14 sty 2026, 22:08 UTC

Earnings

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14 sty 2026, 21:53 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14 sty 2026, 21:53 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14 sty 2026, 21:52 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Announces Positive Profit Alert for 2025

14 sty 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

Citigroup Acting as Financial Advisor to WuXi XDC

14 sty 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC: Aims to Keep Listing Status of BioDlink

14 sty 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14 sty 2026, 21:50 UTC

Market Talk

Earnings

Financial Services Roundup: Market Talk

14 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 sty 2026, 21:49 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14 sty 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14 sty 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Makes Cash Offer for BioDlink International

14 sty 2026, 21:13 UTC

Market Talk

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14 sty 2026, 20:30 UTC

Market Talk

Earnings

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14 sty 2026, 20:13 UTC

Market Talk

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14 sty 2026, 20:08 UTC

Market Talk

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14 sty 2026, 19:33 UTC

Market Talk

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14 sty 2026, 19:06 UTC

Market Talk

Earnings

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

28.82% upside

12 Months Forecast

Average 636.22 USD 28.82%

High 900 USD

Low 527 USD

Based on 12 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

56 / 361 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.